Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase EARLY_PHASE1 1Phase 2/3 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Glioma 2Uterine Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1Breast Neoplasms 1

Interventions

pembrolizumab 3Tirzepatide 2Paclitaxel 2Metformin 2Carboplatin 2tislelizumab 1olaparib 1niraparib 1montelukast 1Taxes 1Tablets 1Radiotherapy, Intensity-Modulated 1Progesterone 1Pafolacianine 1Morphine 1Laparotomy 1Hysterectomy 1Fluorescein 1Ezetimibe 1Dasatinib 1Biopsy 1Atorvastatin 1Anti-Inflammatory Agents, Non-Steroidal 1Anesthesia, Local 1Anesthesia, General 1Anesthesia, Conduction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Endometrial Neoplasms × niraparib × Clear all
NCT05289648 2024-12-19

NIREC

Sir Mortimer B. Davis - Jewish General Hospital

Phase EARLY_PHASE1 Withdrawn
Gynecologic

Uterine Neoplasms, Endometrial Neoplasms, Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡